,,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['breast', 'enhertu', 'destiny-breast04', '$azn', '$dsnky']
has enhertu just redefined her2 negative breast cancer? pfs doubles to 10.1 months over chemo for a 49% risk reduction and os hits 23.9 months (hr 0.64) in her2 low population. my first take on the destiny-breast04 trial at #asco22: $azn $dsnky
Pharma and biotech reporter, found a home at Evaluate Vantage.